Published in JAMA on November 08, 2010
Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol (2011) 1.52
Update on diffuse alveolar hemorrhage and pulmonary vasculitis. Immunol Allergy Clin North Am (2012) 1.07
ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features-outcome. Pediatr Nephrol (2012) 1.05
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol (2014) 0.99
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2013) 0.98
Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther (2012) 0.93
Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Immunol (2011) 0.91
State of the art in the treatment of systemic vasculitides. Front Immunol (2014) 0.90
Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis. J Am Soc Nephrol (2015) 0.87
Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol (2012) 0.86
Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis. Kidney Int Suppl (2011) (2012) 0.86
Current status of outcome measure development in vasculitis. J Rheumatol (2014) 0.85
Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? Nephrol Dial Transplant (2015) 0.84
Treatment of renal manifestations of ANCA-associated vasculitis. J Nephropathol (2013) 0.84
Glomerular disease: perspectives on maintenance therapy in lupus nephritis. Nat Rev Nephrol (2012) 0.83
[Treatment strategies for ANCA-associated vasculitides]. Z Rheumatol (2015) 0.82
Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. Semin Arthritis Rheum (2013) 0.82
Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis). Ther Clin Risk Manag (2014) 0.82
Diagnosis and therapeutic options for peripheral vasculitic neuropathy. Ther Adv Musculoskelet Dis (2015) 0.82
[ANCA-associated vasculitis]. Z Rheumatol (2013) 0.81
Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther (2015) 0.81
Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: case report. Pediatr Rheumatol Online J (2011) 0.81
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol (2015) 0.81
[Update on granulomatosis with polyangitis (GPA, Wegener's granulomatosis)]. Z Rheumatol (2012) 0.81
Therapeutic advances in the treatment of vasculitis. Pediatr Rheumatol Online J (2016) 0.80
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol (2014) 0.80
Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore) (2014) 0.80
Maintenance of clinical remission in ANCA-associated vasculitis. Nat Rev Rheumatol (2012) 0.78
Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis. Semin Arthritis Rheum (2014) 0.78
Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients. Rheumatol Int (2016) 0.78
Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clin Exp Nephrol (2012) 0.77
Recurrence of anti-neutrophil cytoplasmic antibody-associated vasculitis in appropriately immunosuppressed renal transplant patients: a discussion of two cases. Case Rep Nephrol Urol (2013) 0.76
Therapeutic interventions for systemic vasculitis. JAMA (2010) 0.76
Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis. Indian J Nephrol (2016) 0.76
Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis. Clin Exp Rheumatol (2016) 0.76
Gastrointestinal aspects of vasculitides. Nat Rev Gastroenterol Hepatol (2016) 0.76
Sequential strokes in a hyperacute stroke unit. JRSM Open (2014) 0.75
Long-term outcomes in antineutrophil cytoplasmic autoantibody-positive eosinophilic granulomatosis with polyangiitis patients with renal involvement: a retrospective study of 14 Chinese patients. BMC Nephrol (2016) 0.75
The Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western Countries. Kidney Dis (Basel) (2015) 0.75
Practice patterns of ANCA-associated vasculitis: exploring differences among subspecialties at a single academic medical centre. Clin Exp Rheumatol (2014) 0.75
Preventing relapses in antineutrophil cytoplasmic antibody-associated vasculitis. JAMA (2011) 0.75
Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease. Clin Kidney J (2014) 0.75
Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases. Br J Clin Pharmacol (2014) 0.75
Hydralazine-induced pauci-immune glomerulonephritis: intriguing case series with misleading diagnoses. J Community Hosp Intern Med Perspect (2016) 0.75
A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis. Case Rep Rheumatol (2016) 0.75
Updates in ANCA-associated vasculitis. Eur J Rheumatol (2016) 0.75
Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy? Clin Exp Immunol (2016) 0.75
Maintenance immunosuppression in antineutrophil cytoplasmic antibody-associated vasculitis. Am J Kidney Dis (2011) 0.75
Recent advances in understanding and treating vasculitis. F1000Res (2016) 0.75
Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study. Clin Exp Immunol (2014) 0.75
Clinical trial for Japanese patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis: the JMAAV study. Clin Exp Nephrol (2013) 0.75
[Remission maintenance with methotrexate, azathioprine or mycophenolate-mofetil after induction therapy with rituximab for granulomatosis with polyangiitis]. Z Rheumatol (2015) 0.75
[Established medications : new areas of application]. Z Rheumatol (2013) 0.75
Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. Pediatr Nephrol (2017) 0.75
Pediatric granulomatosis with polyangiitis exhibiting prominent central nervous system symptoms. Childs Nerv Syst (2016) 0.75
ANCA Glomerulonephritis and Vasculitis. Clin J Am Soc Nephrol (2017) 0.75
Birmingham vasculitis activity score at diagnosis is a significant predictor of relapse of polyarteritis nodosa. Rheumatol Int (2017) 0.75
[Personalized medicine in the choice of conventional immunosuppressants and disease modifying antirheumatic drugs]. Z Rheumatol (2013) 0.75
Refractory skin lesion, hypertension, and acute kidney injury in a young boy: Answers. Pediatr Nephrol (2017) 0.75
[Current guidelines on ANCA-associated vasculitides : Common features and differences]. Z Rheumatol (2016) 0.75
Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int (2017) 0.75
Issues in trial design for ANCA-associated and large-vessel vasculitis. Nat Rev Rheumatol (2014) 0.75
Treatment of primary systemic necrotizing vasculitides: the role of biotherapies. Clin Exp Nephrol (2013) 0.75
Clinical Trials in Vasculitis. Curr Treatm Opt Rheumatol (2016) 0.75
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med (2010) 8.64
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med (2003) 7.30
Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet (2013) 7.03
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med (2009) 6.61
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med (2014) 5.98
FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet (2007) 5.93
Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA (2007) 5.31
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2005) 4.21
Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis (2006) 3.68
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med (2008) 3.66
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum (2011) 3.60
Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med (2005) 3.49
Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol (2010) 3.48
Lessons from the inquiry into Obstetrics and Gynaecology services at King Edward Memorial Hospital 1990-2000. Aust Health Rev (2003) 3.46
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
The roles of nature and nurture in the recruitment and retention of primary care physicians in rural areas: a review of the literature. Acad Med (2002) 3.42
Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int (2014) 3.40
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum (2007) 3.02
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med (2010) 2.88
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation (2005) 2.49
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis (2003) 2.40
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis (2006) 2.35
Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. J Bone Joint Surg Am (2007) 2.34
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum (2013) 2.28
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis (2010) 2.21
Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2012) 2.19
Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum (2010) 2.11
Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol (2011) 2.11
The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) (2011) 2.05
Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2012) 2.05
Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum (2004) 2.04
Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) (2005) 2.03
The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One (2011) 2.02
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension (2005) 2.01
Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet (2003) 2.00
HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum (2009) 2.00
Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol (2004) 1.99
The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int (2008) 1.94
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis (2011) 1.88
Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant (2005) 1.87
Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis (2009) 1.86
Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant (2008) 1.85
ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant (2005) 1.84
Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum (2007) 1.83
Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol (2006) 1.82
Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol (2012) 1.80
Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant (2012) 1.80
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) (2011) 1.79
Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int (2002) 1.78
Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol (2011) 1.75
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2009) 1.74
Otogenic intracranial complications. a 7-year retrospective review. Am J Otolaryngol (2006) 1.69
Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet (2012) 1.69
ANCA-positive vasculitis. J Am Soc Nephrol (2002) 1.69
Factors associated with internal hip rotation gait in patients with cerebral palsy. J Pediatr Orthop (2006) 1.67
Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol (2013) 1.66
Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) (2014) 1.65
Early complications in proximal humerus fractures (OTA Types 11) treated with locked plates. J Orthop Trauma (2008) 1.62
Antibiotic susceptibility of bacteria infecting total joint arthroplasty sites. J Bone Joint Surg Am (2006) 1.61
Association between multidisciplinary care and survival for elderly patients with chronic kidney disease. J Am Soc Nephrol (2007) 1.60
Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) (2005) 1.60
Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum (2008) 1.59
Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) (2011) 1.59
Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum (2004) 1.58
Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum (2003) 1.52